Read by QxMD icon Read

cancer care, 'radiation therapy,

J Doescher, S Jeske, S E Weissinger, C Brunner, S Laban, E Bölke, T K Hoffmann, T L Whiteside, P J Schuler
BACKGROUND: For head and neck squamous cell cancer (HNSCC), standard therapy consists of surgery, radiation, and/or chemotherapy. Antineoplastic immunotherapy could be an option in an adjuvant setting and is already in palliation. A functional immune system is a prerequisite for successful immunotherapy. However, effects of the standard-of-care therapy on the patients' immune system are not fully understood. METHODS: Peripheral blood mononuclear cells (PBMC) were collected from patients with HNSCC (n = 37) and healthy controls (n = 10)...
April 16, 2018: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
Yvonne L Eaglehouse, Janna Manjelievskaia, Stephanie Shao, Derek Brown, Keith Hofmann, Patrick Richard, Craig D Shriver, Kangmin Zhu
Introduction: Breast cancer care imposes a significant financial burden to U.S. healthcare systems. Health services factors, such as insurance benefit type and care source, may impact costs to the health system. Beneficiaries in the U.S. Military Health System (MHS) have universal healthcare coverage and access to a network of military facilities (direct care) and private practices (purchased care). This study aims to quantify and compare breast cancer care costs to the MHS by insurance benefit type and care source...
April 11, 2018: Military Medicine
Peter Paximadis, Jennifer L Beebe-Dimmer, Julie George, Anne G Schwartz, Antoinette Wozniak, Shirish Gadgeel
INTRODUCTION: The diagnosis of stage I small-cell lung cancer (SCLC) is increasing in incidence with the advent of low-dose screening computed tomography. Surgery is considered the standard of care but there are very few data to guide clinical decision-making. The purpose of this study was to compare outcomes for patients receiving definitive surgery, stereotactic body radiation therapy (SBRT), or external beam radiation therapy (EBRT) for stage I SCLC. PATIENTS AND METHODS: Patients with a primary diagnosis of stage I SCLC were identified in the National Cancer Database...
March 23, 2018: Clinical Lung Cancer
Sadamoto Zenda
Chemotherapy concurrent with radiotherapy has been widely used in clinical practice because the additional benefit on radiotherapy alone had shown. Head and neck cancer: CDDP concurrent with radiotherapy has been a standard treatment for 15years both in definitive setting and postoperative setting. Esophageal cancer: 5-FU/CDDP is the best partner for radiotherapy and appropriate radiation dose has been discussed. Anal cancer: Radical concurrent chemoradiotherapy with 5-FU and mitomycin C(MMC)remains the standard of care for squamous cell carcinoma of the anus...
March 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Ryouichi Tomita, Shigeru Fujisaki, Kenichi Sakurai, Takeo Azuhata, Yuko Takamoto
We report a 50-year-old man with local recurrence of descending colon cancer with ileus obstruction and brain metastasis, 2 years 6 months after initial resection due to perforation of descending colon cancer(Hartmann procedure, D2 lymph node resection, Stage II, tub2). He complained of left upper abdominal pain and abdominal fullness. He also complained of paresis of the right upper extremity and of experiencing convulsions 1 month before admission. He was diagnosed with local recurrence of descending colon cancer, based on findings of contrast radiography and the presence of colonic fiber...
April 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Benjamin Moeller, Ehsan H Balagamwala, Aileen Chen, Kimberly M Creach, Giuseppe Giaccone, Matthew Koshy, Sandra Zaky, George Rodrigues
PURPOSE: To revise the recommendation on the use of concurrent chemotherapy (CC) with palliative thoracic external beam radiation therapy (EBRT) made in the original 2011 American Society for Radiation Oncology guideline on palliative thoracic radiation for lung cancer. METHODS AND MATERIALS: Based on a systematic PubMed search showing new evidence for this key question, the task force felt an update was merited. Guideline recommendations were created using a predefined consensus-building methodology supported by American Society for Radiation Oncology-approved tools for grading evidence quality and recommendation strength...
April 3, 2018: Practical Radiation Oncology
Malek B Hannouf, Eric Winquist, Salaheddin M Mahmud, Muriel Brackstone, Sisira Sarma, George Rodrigues, Peter K Rogan, Jeffrey S Hoch, Gregory S Zaric
PURPOSE: Several genomic tests have recently been developed to identify the primary tumour in cancer of unknown primary tumour (CUP). However, the value of identifying the primary tumour in clinical practice for CUP patients remains questionable and difficult to prove in randomized trials. OBJECTIVE: We aimed to assess the clinical and economic value of primary tumour identification in CUP using a retrospective matched cohort study. METHODS: We used the Manitoba Cancer Registry to identify all patients initially diagnosed with metastatic cancer between 2002 and 2011...
September 6, 2017: PharmacoEconomics Open
Kaitlin M Christopherson, Benjamin D Smith
Radiation therapy is used in many cases of both early and late breast cancer. The authors examine the role of MR imaging as it pertains to radiotherapy planning and treatment approaches for patients with breast cancer. MR imaging can assist the radiation oncologist in determining the best radiation approach and in creating treatment planning volumes. MR imaging may be useful in the setting of accelerated partial breast irradiation. Radiation oncologists should attend to MR breast images, when obtained, to ensure that these imaging findings are taken into consideration when developing a radiation therapy plan...
May 2018: Magnetic Resonance Imaging Clinics of North America
Marc D Schwartz, Beth N Peshkin, Claudine Isaacs, Shawna Willey, Heiddis B Valdimarsdottir, Rachel Nusbaum, Gillian Hooker, Suzanne O'Neill, Lina Jandorf, Scott P Kelly, Jessica Heinzmann, Aliza Zidell, Katia Khoury
PURPOSE: Breast cancer patients who carry BRCA1/BRCA2 gene mutations may consider bilateral mastectomy. Having bilateral mastectomy at the time of diagnosis not only reduces risk of a contralateral breast cancer, but can eliminate the need for radiation therapy and yield improved reconstruction options. However, most patients do not receive genetic counseling or testing at the time of their diagnosis. In this trial, we tested proactive rapid genetic counseling and testing (RGCT) in newly diagnosed breast cancer patients in order to facilitate pre-surgical genetic counseling and testing...
April 2, 2018: Breast Cancer Research and Treatment
M Robyn Andersen, Erin Sweet, Shelly Hager, Marcia Gaul, Fred Dowd, Leanna J Standish
OBJECTIVE: This study sought to describe changes in the health-related quality of life (HRQOL) of women who do and do not seek naturopathic oncology (NO) complementary and alternative medicine (CAM) care during and immediately after breast cancer treatment, and to explore the predictive role of NO CAM care, demographic characteristics, and involvement in decision-making on HRQOL in breast cancer survivors. METHODS: Matched cohorts of breast cancer survivors who did and did not choose to supplement their breast cancer treatment with NO care within 2 years of diagnosis participated...
March 1, 2018: Integrative Cancer Therapies
Peter T Dziegielewski, William J Reschly, Chris G Morris, Reordan Danny DeJesus, Natalie Silver, Brian J Boyce, Inocente Santiago, Robert J Amdur, William M Mendenhall
BACKGROUND: The optimal treatment for T3 glottic cancers continues to be debated. Organ preservation has become the standard of care, but not all tumors respond equally. The purpose of this was to investigate the long-term survival outcomes of organ preservation protocols based on tumor volume. METHODS: A retrospective review of prospectively collected data from 1966 to 2016 was performed. Patients with T3 vocal cord cancer treated with radiation therapy (RT) at the University of Florida were included...
April 2018: Oral Oncology
Y L Liu, C Chin, B Catanese, S M Lee, S Zhan, K Kalinsky, E P Connolly
PURPOSE: Capecitabine has been studied as a radiosensitizer, and our study seeks to examine the association of concurrent capecitabine/radiation therapy (RT) on event-free- (EFS) and overall survival (OS) in women with breast cancer (BC) with residual disease after neoadjuvant chemotherapy (NAC). METHODS/PATIENTS: In a retrospective study of women with BC who received adriamycin/taxane-based NAC from 2004-2016, we identified 21 women administered concurrent capecitabine/RT...
March 28, 2018: Clinical & Translational Oncology
Gokoulakrichenane Loganadane, Zhen Xi, Hao Ping Xu, Noemie Grellier Adedjouma, Louis Bazire, Alain Fourquet, Youlia M Kirova
Purpose: To evaluate loco regional control and describe the patterns of loco regional failure in women with breast cancer irradiated by a previously described post-mastectomy highly conformal electron beam radiotherapy technique. Materials and methods: We included all women irradiated by PMERT for non-metastatic breast cancer (BC) between 2007 and 2011 in our department. All cases of bilateral BC were excluded. All patients who experienced loco regional recurrence have been studied...
June 2017: Clinical and Translational Radiation Oncology
Marc T Roth, Jordan D Berlin
PURPOSE OF REVIEW: The diagnosis of pancreatic cancer carries with it a high mortality rate. Despite advances in the field, this has remained relatively unchanged over the last few decades. Current options for the treatment of resectable pancreatic ductal adenocarcinoma will be reviewed here in conjunction with the historical data that support them. We will focus on updates in treatment guidelines and ongoing clinical trials of interest. RECENT FINDINGS: For localized disease, standard of care includes resection followed by adjuvant chemotherapy ± chemoradiation...
March 26, 2018: Current Oncology Reports
Nikita Malakhov, Anna Lee, Elizabeth Garay, Daniel J Becker, David Schreiber
PURPOSE/OBJECTIVES: While treatment with tumor resection followed by chemoradiation is generally the accepted standard of care for glioblastoma (GBM), the treatment for patients with poor performance status remains uncertain. Therefore we sought to examine patterns of care and survival outcomes among patients with poor performance status utilizing a large hospital database. METHODS/MATERIALS: We queried the National Cancer Database (NCDB) for patients with GBM and Karnofsky performance status (KPS) <60 between 2010 and 2013...
March 22, 2018: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
Stephen A Jannetti, Giuseppe Carlucci, Brandon Carney, Susanne Kossatz, Larissa Shenker, Lukas M Carter, Beatriz Salinas, Christian Brand, Ahmad Sadique, Patrick L Donabedian, Kristen M Cunanan, Mithat Gönen, Vladimir Ponomarev, Brian M Zeglis, Mark M Souweidane, Jason S Lewis, Wolfgang A Weber, John L Humm, Thomas Reiner
The DNA repair enzyme PARP1 is over-expressed in glioblastoma, with overall low expression in healthy brain tissue. Paired with the availability of specific molecularly targeted small molecules for this biomarker, PARP1 is a near-ideal target for novel radiotherapeutics. A successful PARP1-targeted radiotherapeutic would induce DNA damage and apoptosis in cancer cells, while sparing healthy brain tissue. We synthesized a131 I-labeled poly(ADP-ribose) polymerase 1 (PARP1) therapeutic and investigated its pharmacology using in vitro and in vivo methodologies...
March 23, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Tomoko Ueyama, Takeshi Arimura, Koji Takumi, Fumihiko Nakamura, Ryutaro Higashi, Soichiro Ito, Yoshihiko Fukukura, Tomokazu Umanodan, Masanori Nakajo, Chihaya Koriyama, Takashi Yoshiura
OBJECTIVES: To identify risk factors for symptomatic radiation pneumonitis (RP) after stereotactic radiation therapy (SRT) for lung tumours. Methods We retrospectively evaluated 68 lung tumours in 63 patients treated with SRT between 2010 and 2015. RP was graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.0. SRT was delivered at 7.0-12.0 Gy per each fraction, once daily, to a total of 48-64 Gy (median, 50 Gy). Univariate analysis was performed to assess patient- and treatment-related factors, including age, sex, smoking index, pulmonary function, tumour location, serum Krebs von den Lungen-6 value, dose-volume metrics (V5, V10, V20, V30, V40, and VS5), homogeneity index of the planning target volume (PTV), PTV dose, mean lung dose (MLD), contralateral MLD and V2, PTV volume, lung volume and the PTV/lung volume ratio (PTV/Lung)...
March 22, 2018: British Journal of Radiology
Muhammad Shaalan Beg, Jeffrey Meyer
Evidence supporting the synergistic antitumor activity of radiation therapy combined with immune checkpoint inhibitors is rapidly growing. Investigators should consider the characteristics and challenges of gastrointestinal (GI) cancers to evaluate the safety and clinical effectiveness of this combination. In this paper, we present the rationale for exploring this strategy and the opportunities it possesses to challenge our standard of care. We also discuss unique considerations to systematically develop this combination in GI cancers...
February 2018: Journal of Gastrointestinal Oncology
Waqar Haque, Vivek Verma, E Brian Butler, Bin S Teh
Background: Neoadjuvant chemoradiotherapy (CRT) for locally advanced esophageal cancer (EC) may utilize a wide variety of RT doses, without clear consensus to date. This study evaluated national practice patterns between lower dose (LD) (40-41.4 Gy) or higher dose (HD) (50-50.4 Gy) therapy, in addition to differences in survival and postoperative events. Methods: The National Cancer Data Base (NCDB) was queried [2004-2013] for patients with newly-diagnosed cT1a-T4aN0/N+M0 EC that received neoadjuvant CRT followed by esophagectomy...
February 2018: Journal of Gastrointestinal Oncology
Matthew J Farrell, Jehan B Yahya, Catherine Degnin, Yiyi Chen, John M Holland, Mark A Henderson, Jerry J Jaboin, Matthew M Harkenrider, Charles R Thomas, Timur Mitin
PURPOSE: Prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer (LS-SCLC) is considered the standard of care. Meta-analysis of 7 clinical trials indicates a survival benefit to PCI, but all of these trials were conducted in the pre-magnetic resonance imaging (MRI) era. Therefore, routine brain imaging with MRI before PCI-as recommended by National Comprehensive Cancer Network guidelines-is not directly supported by the evidence. Current US practice patterns for patients with LS-SCLC are unknown...
February 23, 2018: Clinical Lung Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"